

## 2009 ACCP Annual Meeting – 30th Anniversary

### ORIGINAL RESEARCH

#### ADR/Drug Interactions

1. Evaluation of the linezolid-serotonergic drug interaction in hospital inpatients.

Amy C. Go, PharmD<sup>1</sup>, Larry K. Golightly, PharmD, BCPS<sup>2</sup>; (1)University of Colorado Hospital, Anschutz Inpatient Pavilion, Aurora, CO; (2)University of Colorado Hospital, Center for Drug Information, Education, and Evaluation, Aurora, CO

2. Relationship between daily dosing frequency, compliance, and healthcare resource utilization: evidence from the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Craig A. Plauschinat, MS; Novartis, East Hanover

#### Ambulatory Care

5. Evaluation of a pain management prescription service at a primary care clinic.

Zachary A. Weber, PharmD<sup>1</sup>, Philip T. Rodgers, Pharm.D, BCPS, CDE, CPP<sup>2</sup>; (1)Purdue University, Indianapolis, IN; (2)Duke University Medical Center, Durham, NC

6. Medication Management Programs at a VA Medical Facility: Effects on Blood Pressure, A Retrospective Analysis.

Jennifer H. Lai, Pharm.D., Timothy C. Chen, PharmD, Mark Bounthavong, Pharm.D.; Veterans Affairs San Diego Healthcare System, San Diego, CA

7. Glycemic control in pharmacist-managed insulin titration versus standard care in an indigent population.

Jamie M. Pitlick, PharmD, Amie D Brooks, PharmD, BCPS; St. Louis College of Pharmacy, St. Louis, MO

8. Using a Clinical Reminder to Increase Statin Use in Diabetics.

Elizabeth J. Peterson, PharmD<sup>1</sup>, Thomas J. Worrall, PharmD, BCPS, FAPhA<sup>2</sup>, Dorothy E. Jenrette, PharmD, BCPS<sup>2</sup>; (1)Ralph H. Johnson VA Medical Center, Charleston, SC; (2)Ralph H. Johnson VA medical center, Charelston, SC

9. Prescribing patterns for the outpatient treatment of constipation in the United States.

Katy Trinkley, PharmD<sup>1</sup>, Kyle Porter, MAS<sup>2</sup>, Milap Nahata, PharmD, MS<sup>1</sup>; (1)Ohio State University College of Pharmacy, Columbus, OH; (2)Ohio State University Center for Biostatistics, Columbus, OH

10E. Predictors of medication adherence in an urban community with healthcare disparities.

Fei Wang, PharmD<sup>1</sup>, Jennifer Colby, PharmD<sup>2</sup>, Rafael Perez-Escamilla, Ph.D.<sup>3</sup>, Jyoti Chhabra, Ph.D.<sup>2</sup>; (1)Hartford Hospital/ University of Connecticut, Hartford, CT; (2)Hartford Hospital, Hartford, CT; (3)University of Connecticut, Storrs, CT

11. Stroke and hypertension awareness in a high-risk population: influence of a pharmacist-initiated intervention in an anticoagulation clinic.

Jennifer L. Clemente, PharmD<sup>1</sup>, Jesse Shuster, Pharm.D.<sup>1</sup>, Candice L. Garwood, Pharm.D.<sup>2</sup>, Peter Whittaker, PhD<sup>3</sup>; (1)Detroit Medical Center, Detroit, MI; (2)Wayne State University, Detroit, MI; (3)Wayne State University School of Medicine, Cardiovascular Research Institute and Dept of Emergency Medicine, Detroit, MI

12. Impact of clinical pharmacy services on hypertension at a Veterans Affairs Community Based Outpatient Clinic.

William Joshua Guffey, Pharm, D., Beth Bryles Phillips, Pharm.D.; University of Georgia College of Pharmacy, Athens, GA

13. Impact of clinical pharmacy services on diabetes mellitus at a Veterans Affairs Community Based Outpatient Clinic.

William Joshua Guffey, Pharm, D.<sup>1</sup>, Beth Bryles Phillips, Pharm.D.<sup>2</sup>; (1)University of Georgia College of Pharmacy, Athens, GA; (2)University of Georgia, Athens, GA

14. Hepatitis C Virus (HCV): Evaluation of laboratory assessments prior to treatment and the effectiveness of a pharmacist-managed treatment program.

Lori B. Hornsby, PharmD<sup>1</sup>, Ryan Crossman, PharmD<sup>2</sup>, Hardik Patel, P4<sup>3</sup>, Alison O. Baker, P4<sup>3</sup>; (1)Auburn University Harrison School of Pharmacy, Phenix City, AL; (2)Columbus Regional Healthcare System, Columbus, GA; (3)Auburn University Harrison School of Pharmacy, Auburn, AL

15. Anticoagulation stability is determined by the consistency and quantity of vitamin K consumption.

Jennifer L. Clemente, Pharm.D.<sup>1</sup>, Candice L. Garwood, Pharm.D.<sup>2</sup>, Jennifer L. Johnson, Pharm.D., Candidate<sup>3</sup>, Peter Whittaker, PhD<sup>4</sup>; (1)Detroit Medical Center, Detroit, MI; (2)Wayne State University, Detroit, MI; (3)Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI; (4)Wayne State University School of Medicine, Cardiovascular Research Institute and Dept of Emergency Medicine, Detroit, MI

#### Endocrinology

64E. Long-term use of colesevelam HCl in subjects with type 2 diabetes mellitus (T2DM) on metformin therapy. Harold E. Bays, MD, FACP<sup>1</sup>, Allison B. Goldfine, MD<sup>2</sup>, Michael R. Jones, PhD<sup>3</sup>, Stacey L. Abby, PharmD<sup>3</sup>, Soamnauth Misir, PharmD<sup>3</sup>, Sukumar Nagendran, MD<sup>3</sup>; (1)Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY; (2)Joslin Diabetes Center, Boston, MA; (3)Daiichi Sankyo, Inc., Parsippany, NJ

65. Impact of Pharmacist Intervention on Glycemic Control and Cardiovascular Risks Management in Hypertensive Type 2 Diabetic Patients in Primary Care Settings.

Vivian WY Lee, PharmD, Kitty KY Chu, BSc, Sinki SK Lam, BSc, Wilson YS Leung, PhD; The Chinese University of Hong Kong, Shatin, Hong Kong

66. Vitamin D Status and Obesity.

Daniel M. Riche, Pharm.D., BCPS, CDE<sup>1</sup>, Honey E. East, M.D.<sup>2</sup>, Krista D. Riche, Pharm.D., BCPS<sup>3</sup>; (1)University of Mississippi Schools of Pharmacy and Medicine, Jackson, MS; (2)University of Mississippi School of Medicine, Jackson, MS; (3)Mississippi Baptist Medical Center, Jackson, MS

68E. Determining predictors of response to exenatide in type 2 diabetes.

Sarah L. Anderson, PharmD<sup>1</sup>, Jennifer Trujillo, PharmD<sup>1</sup>, Joseph Saseen, PharmD<sup>1</sup>, Michael T. McDermott, M.D.<sup>2</sup>; (1)University of Colorado Denver School of Pharmacy, Aurora, CO; (2)University of Colorado Denver, School of Medicine, Aurora, CO

### **Gastroenterology**

69. SSRI prophylaxis vs. rescue treatment of interferon-induced depression in Hepatitis C patients.

Septima B. Hong, Pharm.D., BCPS<sup>1</sup>, Michele M. Spence, Ph.D.<sup>1</sup>, Jim Chan, Pharm.D., Ph.D.<sup>2</sup>; (1)Kaiser Permanente Medical Care Program, Downey, CA; (2)Kaiser Permanente Medical Care Program, Oakland, CA

### **Gout**

73E. Documentation of fewer gout flares after long-term urate-lowering treatment.

Michael A. Becker, MD<sup>1</sup>, H. Ralph Schumacher Jr., MD<sup>2</sup>, Saima Chohan, MD<sup>1</sup>, Patricia MacDonald, NP<sup>3</sup>, Barbara Hunt, MS<sup>3</sup>, Robert L. Jackson, MD<sup>3</sup>; (1)University of Chicago, Pritzker School of Medicine, Chicago, IL; (2)University of Pennsylvania School of Medicine, Veterans Affairs Medical Center, Philadelphia, PA; (3)Takeda Global Research & Development Center, Inc., Deerfield, IL

### **Health Services Research**

76. The impact of pharmacist-provided risk factor screening and education on health-promoting behaviors.

Leslie A. Mooney, Pharm.D., Amy M. Franks, Pharm.D.; University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR

### **Hematology/Anticoagulation**

77. Phytonadione for excessive anticoagulation: a community hospital's experience in improving utilization. Luigi Brunetti, Pharm.D.<sup>1</sup>, Fatema Dhanaliwala, RPh<sup>2</sup>, Nancy Doherty, MS, RPh<sup>2</sup>, Stuart Vigdor, RPh<sup>2</sup>; (1)Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ; (2)Somerset Medical Center, Somerville, NJ

78. Thrombotic Risk Stratification in Residents of Long Term Care Facilities.

Barbara Zarowitz, PharmD, Allen Lefkovitz, PharmD, Terrence O'Shea, PharmD, Eric Tangalos, MD, Steven Deitelzweig, MD, Henry Bussey, PharmD, Edith Nutescu, PharmD, Barbara Resnick, RNP, Arthur Wheeler, MD; Omnicare, Inc., Livonia, MI

79. Safety and efficacy of very low dose unfractionated heparin continuous infusion for the treatment of venous thromboembolism in hematologic malignancy patients with thrombocytopenia.

Jennifer Baldock, PharmD, Courtney Yuen, PharmD, BCOP, Helen Wu, PharmD, BCOP; University of California - San Francisco, San Francisco, CA

80. Evaluation of a heparin dosing nomogram with emphasis on special patient populations.

Lynette R. Moser, Pharm.D.<sup>1</sup>, Kathryn Weber, Pharm.D.<sup>2</sup>, Melissa Lipari, Pharm.D., Candidate, 2010<sup>3</sup>, Kathleen McGaffey, Pharm.D., Candidate, 2010<sup>3</sup>, Deborah Virant-Young, Pharm.D.<sup>4</sup>; (1)Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI; (2)St. John Hospital and Medical Center, Department of Pharmacy Services, Detroit, MI; (3)Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI; (4)St. John Hospital and Medical Center, Detroit, MI

81. Appropriateness of a weight-based heparin nomogram in obese patients.

Jennifer N. Riney, Pharm.D., James M. Hollands, Pharm.D., Jennifer R. Smith, Pharm.D., Eli N. Deal, Pharm.D.; Barnes-Jewish Hospital, Saint Louis, MO

82. Pre-test Probability Scoring System (4Ts) may assist in optimization of resource utilization in heparin-induced thrombocytopenia (HIT) in a community hospital.

Anna Dushenkov, PharmD, Agnes Koniecka, PharmD, Valeriy Kraydman, MD, Nick Fitterman, MD, Garry Stone, MD, Jack Mateuynas, RPh; Huntington Hospital NS LIJ Health System, Huntington, NY

83. Topical recombinant human thrombin at a concentration of 1000 IU/mL controls the negative effects

of heparin and Clopidogrel on hemostasis and clot durability.

*Steven Hughes, PhD*, Paul D. Bishop, PhD, Richard Garcia, BS, Tracy Zhang, MS, W. Allan Alexander, MD; ZymoGenetics, Inc., Seattle, WA

## **HIV/AIDS**

87E. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each in combination with abacavir (ABC)/lamivudine (3TC), after initial suppression with ABC/3TC + ATV/r in HIV infected patients: 84 week results of the ARIES trial.

*Mark S. Shaefer, PharmD<sup>1</sup>*, Kathleen Squires, MD<sup>2</sup>, Benjamin Young, MD, PhD<sup>3</sup>, Edwin DeJesus, MD<sup>4</sup>, Nicholas C. Bellos, MD<sup>5</sup>, Daniel Murphy, MD<sup>6</sup>, Denise H. Sutherland-Phillips, MD<sup>1</sup>, Henry Zhao, Ph.D.<sup>1</sup>, Lisa G. Patel, PharmD<sup>1</sup>, Lisa L. Ross, Ph.D.<sup>1</sup>, Paul G. Wannamaker, BS<sup>1</sup>; (1)GlaxoSmithKline, Research Triangle Park, NC; (2)Thomas Jefferson University, Philadelphia, PA; (3)Division of General Internal Medicine, University of Colorado, Denver, CO; (4)Orlando Immunology Center, Orlando, FL; (5)Southwest Infectious Disease Associates, Dallas, TX; (6)Clinique Medicale L'Actuel, Montreal, QC, Canada

88. Survey assessing HIV knowledge/skill and continuing education interest of pharmacists attending continuing education programs in Massachusetts.

*Anela Stanic, Pharm.D.<sup>1</sup>*, Denis V. Rybin, MS<sup>2</sup>, Anita Young, MEd, RPh<sup>3</sup>, Caroline Zeind, Pharm.D.<sup>4</sup>, Helene Hardy, Pharm.D., M.Sc.<sup>5</sup>; (1)Boston Medical Center and Massachusetts College of Pharmacy, Boston, MA; (2)Boston University School of Public Health, Data Coordinating Center, Boston, MA; (3)Northeastern University School of Pharmacy, Boston, MA; (4)Massachusetts College of Pharmacy and Health Sciences, Boston, MA; (5)Boston Medical Center, Boston, MA

89. In vivo levels of ritonavir (RTV), lopinavir (LPV), Efavirenz (EFV) over time after intraperitoneal (IP) injection of antiretroviral (AR) PLGA nanoparticle (NP). *Christopher J. Destache, Pharm.D., FCCP*, Todd Belgum, B.S., Annemarie Shibata, Ph. D., Alekha K. Dash, Ph. D.; Creighton University School of Pharmacy and Health Professions, Omaha, NE

90E. Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) in the HEAT study. *Parul Patel, PharmD<sup>1</sup>*, Grace A. McComsey, M.D.<sup>2</sup>, Kimberly Y. Smith, MD<sup>3</sup>, Nicholas C. Bellos, MD<sup>4</sup>, Louis Sloan, MD<sup>5</sup>, Phillip Lackey, M.D.<sup>6</sup>, Princy N. Kumar, MD<sup>7</sup>, Denise H Sutherland-Phillips, MD<sup>1</sup>, Linda H Yau, Ph.D.<sup>1</sup>, Mark S Shaefer, Pharm.D.<sup>1</sup>; (1)GlaxoSmithKline, Research Triangle Park, NC; (2)Case

School of Medicine, Cleveland, OH; (3)Rush University Medical Center, Chicago, IL; (4)Southwest Infectious Disease Associates, Dallas, TX; (5)North Texas IDC, Dallas, TX; (6)ID Consultants, Charlotte, NC; (7)Georgetown University, Washington, DC

91E. Steady-State Pharmacokinetics (PK) of Maraviroc (MVC) and Amprenavir (APV) Alone and in Combination After MVC is Given Twice-daily with Unboosted or Ritonavir (r)-boosted Fosamprenavir (FPV) Once- or Twice-daily in Fasted Healthy Volunteers.

Andrew D. Luber, PharmD<sup>1</sup>, David V. Condoluci, DO<sup>2</sup>, P. Dawn Slowinski, MSN<sup>2</sup>, Stan G. Louie, PharmD<sup>3</sup>, Nick Mordwinkin, PharmD<sup>3</sup>, Keith A. Pappa, PharmD<sup>4</sup>, *Gary E. Pakes, PharmD<sup>4</sup>*; (1)Consultant, Division of Infectious Diseases, Voorhees, NJ; (2)Garden State Infectious Diseases Associates, P.A., Voorhees, NJ; (3)University of Southern California, School of Pharmacy, Los Angeles, CA; (4)GlaxoSmithKline, Research Triangle Park, NC

92. Steady-State Pharmacokinetics (PK) of Fosamprenavir (FPV) and Raltegravir (RAL) Alone and Combined with Unboosted and Ritonavir-Boosted FPV in Fasted Healthy Volunteers.

Andrew D. Luber, PharmD<sup>1</sup>, P. Dawn Slowinski, MSN<sup>2</sup>, Edward P. Acosta, PharmD<sup>3</sup>, *Gary E. Pakes, PharmD<sup>4</sup>*, Keith A. Pappa, PharmD<sup>4</sup>, David V. Condoluci, DO<sup>2</sup>; (1)Consultant, Division of Infectious Diseases, Voorhees, NJ; (2)Garden State Infectious Diseases Associates, P.A., Voorhees, NJ; (3)University of Alabama at Birmingham, Birmingham, AL; (4)GlaxoSmithKline, Research Triangle Park, NC

93. Immunologic Response to Hepatitis B (Hep B) Vaccination in Human Immunodeficiency Virus (HIV)-Infected Patients.

*Bernadette Johnson, PharmD<sup>1</sup>*, Renee Mercier, PharmD<sup>1</sup>, Karla Thornton, MD<sup>1</sup>, Wenoah Veikley, BScN<sup>2</sup>, Trevor Hawkins, MD<sup>2</sup>; (1)University of New Mexico Health Sciences Center, Albuquerque, NM; (2)Southwest Care Clinic, Santa Fe, NM

94E. Therapeutic Amprenavir (APV) and Abacavir (ABC) Concentrations in CSF of HIV-Infected Patients Treated with Fosamprenavir (FPV)-Containing Antiretroviral Regimens.

*Scott L. Letendre, MD<sup>1</sup>*, Edmund V. Capparelli, Pharm.D.<sup>2</sup>, Brookie M. Best, PharmD<sup>2</sup>, Steven S. Rossi, Ph.D.<sup>2</sup>, Lauren F. Way, CMA<sup>3</sup>, Igor Grant, MD<sup>3</sup>, Ronald J. Ellis, MD, PhD<sup>4</sup>; (1)Department of Medicine, University of California, San Diego, San Diego, CA; (2)Department of Pediatrics, University of California, San Diego, San Diego, CA; (3)Department of Psychiatry, University of California, San Diego, San Diego, CA; (4)Department of Neurosciences, University of California, San Diego, San Diego, CA

## **Medication Safety**

128. Patient safety initiative for patients on concomitant amiodarone and simvastatin therapy.  
Sahar Karimi, PharmD, Cherylyn Beckey, PharmD, *David Parra, PharmD*, Augustus R Hough, PharmD; West Palm Beach Veterans Affairs Medical Center, West Palm Beach, FL

129. A retrospective evaluation of the safety of desmopressin as a hemostatic agent in renally impaired patients.  
*Jeanne J. Ventura, Pharm.D.*, Maria K. Stubbs, RPh, Chai L. Low, Pharm.D.; Veterans Affairs San Diego Healthcare System, San Diego, CA

130. Investigation of the implementation of an anticoagulation protocol.  
*Andrew J. Crannage, Pharm.D.*, Julie A. Murphy, Pharm.D.; St. Louis College of Pharmacy and St. John's Mercy Medical Center, St. Louis, MO

131. Persistence of antibodies to the topical hemostat bovine thrombin.  
*C. Duane Randleman, MD<sup>1</sup>*, Neil K. Singla, MD<sup>2</sup>, Kenneth L. Renkens Jr., MD<sup>3</sup>, John Pribble, PharmD<sup>4</sup>, Allan Alexander, MD<sup>4</sup>; (1)Cardio Thoracic Surgeons, PC, Birmingham, AL; (2)Lotus Clinical Research, Inc., Pasadena, CA; (3)Indiana Spine Group, Indianapolis, IN; (4)ZymoGenetics, Inc., Seattle, WA

132. Prevalence of medication sharing and use of "left over" medications in an inner city urban population.  
*Nima M. Patel, PharmD, BCPS<sup>1</sup>*, Lawrence Ward, MD<sup>2</sup>; (1)Temple University School of Pharmacy, Philadelphia, PA; (2)Temple University School of Medicine, Philadelphia, PA

133. Evaluation of incorporating trigger tool into daily pharmacy monitoring for increased detection and reporting of medication related harm.  
*Christine B. Rualo, Pharm.D.<sup>1</sup>*, Danny Vu, Pharm.D.<sup>1</sup>, Ronald Floyd, Pharm.D.<sup>2</sup>, Grant Lum, Pharm.D.<sup>1</sup>; (1)Sharp Chula Vista Medical Center, Chula Vista, CA; (2)Sharp Mary Birch Hospital for Women, San Diego, CA

### **Nephrology**

134. Gamma-glutamyl transpeptidase expression and activity in human kidney tissue.  
*Stacy Shord, PharmD, BCOP*, Shitalben R. Patel, MS; University of Illinois at Chicago College of Pharmacy, Chicago, IL

135. Vancomycin clearance during modeled slow low efficiency dialysis.  
*Mariann D. Churchwell, Pharm.D.*; University of Toledo College of Pharmacy, Toledo, OH

### **Neurology**

136. A clinical pharmacology study to determine the selective and non-selective doses of rasagiline, a monoamine oxidase type B inhibitor.  
*Jack J. Chen, PharmD<sup>1</sup>*, Liat Adar, PhD<sup>2</sup>, Tamar Goren, PhD<sup>2</sup>, Nissim Sasson, MA<sup>2</sup>, Yoni Weiss, MD, MBA<sup>2</sup>; (1)Loma Linda University, Loma Linda, CA; (2)Teva Pharmaceutical Industries Ltd, Netanya, Israel

137. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment with immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C): summary of a randomized placebo-controlled study.  
*Peter Donofrio, MD<sup>1</sup>*, Vera Bril, MD<sup>2</sup>, Marinos C. Dalakas, MD<sup>3</sup>, Chunqin Deng, PhD<sup>4</sup>, Kim Hanna, MSc<sup>4</sup>, Hans-Peter Hartung, MD<sup>5</sup>, Richard AC Hughes, MD<sup>6</sup>, Norman Latov, MD<sup>7</sup>, Ingemar SJ Merkies, MD<sup>8</sup>, Pieter A van Doorn, MD<sup>8</sup>; (1)Department of Neurology, Vanderbilt University, Nashville, TN; (2)Division of Neurology, University Health Network, Toronto, ON, Canada; (3)Clinical Neuroscience, Imperial College, London, United Kingdom; (4)Talecris Biotherapeutics, Research Triangle Park, NC; (5)Department of Neurology, Heinrich Heine University, Düsseldorf, Germany; (6)Department of Clinical Neuroscience, King's College and Guy's Hospital, London, United Kingdom; (7)Peripheral Neuropathy Center, Cornell University, New York, NY; (8)Department of Neurology, Erasmus MC, Rotterdam, Netherlands

138. Open-label naturalistic study of pregabalin for cervical dystonia and other hyperkinetic movement disorders (HMDs): effectiveness and tolerability.  
*Jack J. Chen, PharmD<sup>1</sup>*, Michelle Prideaux, PharmD<sup>2</sup>, David M. Swope, MD<sup>1</sup>; (1)Loma Linda University, Loma Linda, CA; (2)Loma Linda University Medical Center, Loma Linda, CA

139E. Mortality after Intracerebral Hemorrhage is Associated with Renal Dysfunction.  
*Denise H. Rhoney, Pharm.D.<sup>1</sup>*, Dennis Parker, Pharm.D.<sup>1</sup>, Scott Millis, PhD<sup>2</sup>, Peter Whittaker, PhD<sup>3</sup>; (1)Wayne State University, Detroit, MI; (2)Rehabilitation Institute of Michigan, Detroit, MI; (3)Wayne State University School of Medicine, Cardiovascular Research Institute and Dept of Emergency Medicine, Detroit, MI

### **Ophthalmology**

145E. The Ocular Comfort and Safety of the Novel Anti-Histamine Bepotastine Besilate Ophthalmic Solution 1.5% in a Healthy Pediatric Population.  
Eugene E. Protzko, MD<sup>1</sup>, Paul J. Gomes, MD<sup>2</sup>, *Jon I. Williams, PhD<sup>3</sup>*, James A. Gow, MD<sup>3</sup>, Timothy R. McNamara, PharmD<sup>3</sup>; (1)Seidenberg-Protzko Eye Associates, Bel Air, MD; (2)ORA Clinical Research & Development, Inc., North Andover, MA; (3)ISTA Pharmaceuticals, Inc., Irvine, CA

146E. Bepotastine besilate ophthalmic solution reduces nasal symptoms in the Conjunctival Allergen Challenge (CAC) clinical model.

Gail L. Torkildsen, MD<sup>1</sup>, Paul J. Gomes, MD<sup>1</sup>, Jon I. Williams, PhD<sup>2</sup>, James A. Gow, MD<sup>2</sup>, Mark B. Abelson, MD<sup>1</sup>, Timothy R. McNamara, PharmD<sup>2</sup>; (1)ORA Clinical Research & Development, Inc., North Andover, MA; (2)ISTA Pharmaceuticals, Inc., Irvine, CA

147E. Bepotastine Besilate Ophthalmic Solution 1% Reduces Ear or Palate Pruritus with Rapid Onset in a Clinical Model of Allergic Conjunctivitis.

Gail L. Torkildsen, MD<sup>1</sup>, Paul J. Gomes, MD<sup>1</sup>, Jon I. Williams, PhD<sup>2</sup>, James A. Gow, MD<sup>2</sup>, Mark B. Abelson, MD<sup>1</sup>, Timothy R. McNamara, PharmD<sup>2</sup>; (1)ORA Clinical Research & Development, Inc., North Andover, MA; (2)ISTA Pharmaceuticals, Inc., Irvine, CA

#### **other**

148. Recombinant Human Hyaluronidase-Facilitated Subcutaneous Fluid Administration Techniques.

George Harb, MD, MPH; Baxter Healthcare Corporation, New Providence

#### **Pain Management/Analgesia**

149E. Methylnaltrexone for the Treatment of Postoperative Ileus: Combined Safety Analysis From Two Phase 3 Studies.

Seth Schulman, MD, Evan Tzanis, MD, Bruce Randazzo, MD; Wyeth Pharmaceuticals, Inc., Collegeville, PA

150E. Adherence of and fentanyl absorption from fentanyl buccal soluble film (FBSF) under various administration conditions.

Niraj Vasisht, PhD<sup>1</sup>, Jeffrey G. Stark, PhD<sup>2</sup>, Andrew L. Finn, PharmD<sup>1</sup>, Larry N. Gever, PharmD<sup>3</sup>; (1)BioDelivery Sciences International, Inc., Raleigh, NC; (2)CEDRA Corporation, Austin, TX; (3)Meda Pharmaceuticals, Inc., Somerset, NJ

151E. Fentanyl buccal soluble film (FBSF) offers high absolute bioavailability and demonstrates faster absorption and greater exposure to fentanyl oral transmucosal fentanyl citrate (OTFC).

Niraj Vasisht, PhD<sup>1</sup>, Jeffrey G. Stark, PhD<sup>2</sup>, Andrew L. Finn, PharmD<sup>1</sup>, Larry N. Gever, PharmD<sup>3</sup>; (1)BioDelivery Sciences International, Inc., Raleigh, NC; (2)CEDRA Corporation, Austin, TX; (3)Meda Pharmaceuticals, Inc., Somerset, NJ

152. A retrospective review of the effect of fentanyl patch on postoperative pain management in orthopedic surgery.

Sandy R. Liu, Pharm.D., Jeff Nemeth, Pharm.D., MPA, CACP; Englewood Hospital and Medical Center, Englewood, NJ

#### **Pediatrics**

153E. The Safety of the Anti-Histamine Bepotastine Besilate Ophthalmic Solution in a Healthy Pediatric Population from Ten to Seventeen Years of Age.

Eugene E. Protzko, MD<sup>1</sup>, Jon I. Williams, PhD<sup>2</sup>, James A. Gow, MD<sup>2</sup>, Paul J. Gomes, MD<sup>3</sup>, Mark B. Abelson, MD<sup>3</sup>, Timothy R. McNamara, PharmD<sup>2</sup>; (1)Seidenberg-Protzko Eye Associates, Bel Air, MD; (2)ISTA Pharmaceuticals, Inc., Irvine, CA; (3)ORA Clinical Research & Development, Inc., North Andover, MA

154E. Recombinant human hyaluronidase-facilitated subcutaneous versus intravenous fluid administration for rehydration of infants and children.

George Maher, DO, FAAP, FACOP, CPI<sup>1</sup>, Sharon E. Mace, MD, FACEP, FAAP<sup>2</sup>, Barry Hahn, MD, FACEP<sup>3</sup>, George Harb, MD, MPH<sup>4</sup>; (1)Memorial Children's Hospital, South Bend, IN; (2)Cleveland Clinic, Cleveland, OH; (3)Staten Island University Hospital, Staten Island, NY; (4)Baxter Healthcare Corporation, New Providence, NJ

155E. Association between recent and future asthma exacerbations in pediatric patients with severe or difficult-to-treat asthma.

Tmirah Haselkorn, PhD<sup>1</sup>, Jim E Fish, MD<sup>1</sup>, Marc Massanari, PharmD<sup>2</sup>; (1)Genentech, Inc., South San Francisco, CA; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ

156E. Add-on omalizumab significantly reduces exacerbation rates in children with inadequately controlled moderate-severe allergic (IgE-mediated) asthma.

Henry Milgrom, MD<sup>1</sup>, Richard L. Wasserman, MD, PhD<sup>2</sup>, Angel Fowler-Taylor, MD<sup>3</sup>, Carlos Fernandez Vidaurre, MD<sup>3</sup>, M. Blogg, MD<sup>4</sup>, Howard Fox, MD<sup>4</sup>; (1)University of Colorado Health Sciences Center, Denver, CO; (2)Dallas Allergy Immunology, Dallas, TX; (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (4)Novartis Horsham Research Centre, Horsham, England

157. Pharmacokinetic and therapeutic evaluation of two doses of aminophylline administered as multiple intermittent infusion to Iranian premature neonates.

Afsaneh Vazin, PharmD<sup>1</sup>, Mohammad Moslehi, PharmD<sup>1</sup>, Mehrdad Hamidi, PhD<sup>1</sup>, Narjes Phishva, MD<sup>2</sup>; (1)faculty of pharmacy, Shiraz university of medical sciences, Shiraz, Iran; (2)Faculty of medicine, shiraz university of medical sciences, Shiraz, Iran

158. Duration of neonatal ICU stay does not increase with longer phototherapy for hyperbilirubinemia within three weeks.

Zon-Min Lee Sr., master; Department of Pharmacy, Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan

#### **Pharmacoeconomics/Outcomes**

159. Economic impact of immune mediated coagulopathy in the post-operative patient.

*M. Scot Maxon, PharmD*, Gerald Engley, PharmD, Karen Wisont, MS, Tony Russell, PhD; ZymoGenetics, Seattle, WA

160E. Clinical and economic outcomes in cancer chemotherapy patients initiated on erythropoietic stimulating agents (ESAs) at hemoglobin (Hb) levels < 10 g/dL.

Tanya Burton, PhD<sup>1</sup>, Kay Larholt, ScD<sup>1</sup>, Elizabeth Apgar, MPH<sup>1</sup>, Chris L. Pashos, PhD<sup>1</sup>, *R. Scott McKenzie, MD<sup>2</sup>*, Catherine T. Piech, MBA<sup>2</sup>; (1)Abt Bio-Pharma Solutions, Inc., Lexington, MA; (2)Centocor Ortho Biotech Services, LLC, Horsham, PA

162. A cost-efficacy analysis of certolizumab and infliximab in the treatment of rheumatoid arthritis.

*Boxiong Tang, MD, PhD*, Chureen T. Carter, PharmD, MS, R. Scott McKenzie, MD, Catherine T. Piech, MBA; Centocor Ortho Biotech Services, LLC, Horsham, PA

163E. Compliance, Persistence, and Outcomes in Patients with Alzheimer's Disease Treated with Oral Cholinesterase Inhibitors.

Francis Vekeman, MA<sup>1</sup>, Francois Laliberte, MA<sup>1</sup>, Kristijan Kahler, PhD, RPh<sup>2</sup>, Nikita Mode-Patel, PharmD<sup>2</sup>, *Amit S. Kulkarni, PhD<sup>2</sup>*, Mei Sheng Duh, MPH, ScD<sup>3</sup>, Patrick Lefebvre, MA<sup>1</sup>; (1)Groupe d'analyse, Ltée, Montreal, QC, Canada; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)Analysis Group, Inc., Boston, MA

164E. Emergent Use of Antipsychotic Drugs in Patients with Alzheimer's Disease Treated With Rivastigmine Versus Donepezil: Evidence from Health Claims Data.

Douglas Scharre, M.D., C.M.D.<sup>1</sup>, Francis Vekeman, MA<sup>2</sup>, Patrick Lefebvre, MA<sup>2</sup>, Kristijan Kahler, PhD, RPh<sup>3</sup>, Nikita Mode-Patel, PharmD<sup>3</sup>, *Amit S. Kulkarni, PhD<sup>3</sup>*, Mei Sheng Duh, MPH, ScD<sup>4</sup>; (1)Ohio State University, Department of Neurology, Columbus, OH; (2)Groupe d'analyse, Montréal, QC, Canada; (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (4)Analysis Group, Inc., Boston, MA

165. Adherence to aliskiren in a real-world environment.

Feng Zeng, PhD<sup>1</sup>, Kristin Hanson, PharmD<sup>2</sup>, Sara Gao, PhD<sup>1</sup>, Bimal V. Patel, PharmD, MS<sup>1</sup>, *Helen Lau, MS<sup>2</sup>*; (1)MedImpact Healthcare Systems, San Diego, CA; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ

166. Risk of osteoporotic fracture and warfarin exposure: a case-control study.

*Kristine B. Ebright, PharmD, BCPS*, Michele Spence, PhD; Kaiser Permanente Drug Information Services, Downey, CA

167. Blood-stream infections and their attributable length of stay: does delivery of parenteral nutrition via multi-chamber bag have any impact?.

*Todd W. Canada, Pharm.D., BCNSP<sup>1</sup>*, Robin S. Turpin, PhD<sup>2</sup>, Katie Williams, MPH<sup>3</sup>, Shane Scott, PharmD<sup>2</sup>; (1)University of Texas M.D. Anderson Cancer Center, Houston, TX; (2)Baxter Healthcare, Deerfield, IL; (3)United BioSource, Lexington, MA

168. Adherence and persistence of antiplatelet therapy following ischemic stroke/TIA hospitalization.

*Karina L. Berenson, MPH*, Elisabetta Malangone, MS, Lee Stern, MS, Roman Casiano, MS; Analytica International, New York, NY

### **Pharmacoepidemiology**

171. Differences in Predictors of Elevated Vancomycin MIC among Patients with MSSA and MRSA Infections.

*S. Lena Kang-Birken, Pharm.D.*; Santa Barbara Cottage Hospital, Santa Barbara, CA

### **Pharmacogenomics/Pharmacogenetics**

172. UGT2B7 and ABCC2 polymorphisms modify mycophenolic acid pharmacokinetics in islet transplant patients: a preliminary report.

*Mary HH Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS<sup>1</sup>*, Marie-Odile Benoit-Biancamano, DMV, MSc, PhD-Candidate<sup>2</sup>, Lillian S. L. Ting, BSc, MSc, PhD<sup>3</sup>, Mai Al-Khatib, BSc(Pharm), MSc<sup>4</sup>, R. Jean Shapiro, MD, FRCPC<sup>5</sup>, Nilufar Partovi, BSc(Pharm), PharmD<sup>6</sup>, Chantal Guillemette, PhD<sup>7</sup>; (1)University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada; (2)CHUQ Research Centre, Laval University, Quebec City, QC, Canada; (3)University of British Columbia, Vancouver, BC, Canada; (4)University of British Columbia, Vancouver, BC; (5)University of British Columbia, Vancouver General Hospital, Vancouver; (6)University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; (7)CHUL Research Center, Laval University, Quebec City, QC

173. Pharmacogenetics of mycophenolate and UGT and ABCC2 polymorphisms in thoracic transplant recipients.

Lillian S. L. Ting, BSc, MSc, PhD<sup>1</sup>, Marie-Odile Benoit-Biancamano, DMV, MSc, PhD-Candidate<sup>2</sup>, Olivier Bernard, BSc.(Pharm), MSc.<sup>3</sup>, K. Wayne Riggs, BSc(Pharm), PhD<sup>1</sup>, Chantal Guillemette, PhD<sup>3</sup>, *Mary HH Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS<sup>4</sup>*; (1)University of British Columbia, Vancouver, BC, Canada; (2)CHUQ Research Centre, Laval University, Quebec City, QC; (3)CHUL Research Center, Laval University, Quebec City, QC; (4)University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

174. A Survey on Warfarin Pharmacogenetic Testing among Anticoagulation Providers.

*Jaekyu Shin, Pharm.D.*, Maha Kadafour, Pharm.D., Roshanak Haugh, Pharm.D., Monica Posin, Pharm.D., Steven Kayser, Pharm.D.; University of California San Francisco, San Francisco

175. Apolipoprotein E genotype influences time to stable warfarin dosing in African Americans.

*Christopher P. Butler, Pharm.D.*<sup>1</sup>, Shitalben R. Patel, M.S.<sup>1</sup>, Taimour Y. Langae, PhD<sup>2</sup>, Edith A. Nutescu, Pharm.D.<sup>1</sup>, Nancy L. Shapiro, Pharm.D.<sup>1</sup>, Larisa H. Cavallari, Pharm.D.<sup>1</sup>; (1)University of Illinois at Chicago, Chicago, IL; (2)University of Florida, Gainesville, FL

176. Cyclooxygenase-2 and Endothelial Nitric Oxide Synthase Polymorphisms and Endothelial Function in Coronary Artery Disease Patients.

*Kyle J. Ellis, Pharm.D.*<sup>1</sup>, Almasa Bass, Pharm.D.<sup>1</sup>, Katherine N. Theken, Pharm.D.<sup>1</sup>, Melissa Caughey, R.V.T.<sup>2</sup>, Lauranell H. Burch, Ph.D.<sup>3</sup>, Nancy J. Brown, M.D.<sup>4</sup>, Darryl C. Zeldin, M.D.<sup>3</sup>, George A. Stouffer, M.D.<sup>2</sup>, Alan L. Hinderliter, M.D.<sup>2</sup>, Craig R. Lee, Pharm.D., Ph.D.<sup>1</sup>; (1)Eshelman School of Pharmacy, UNC-Chapel Hill, Chapel Hill, NC; (2)School of Medicine, UNC-Chapel Hill, Chapel Hill, NC; (3)National Institute of Environmental Health Sciences, Research Triangle Park, NC; (4)School of Medicine, Vanderbilt University, Nashville, TN

### **prescription error**

193. Detection of prescription errors by a unit-based clinical pharmacist in a nephrology ward.

*Ghazal Vessal, PharmD, PhD*; Shiraz University of Medical Sciences, Shiraz, Iran

### **Sleep disorders**

205. Comparison between armodafinil and modafinil for the treatment of excessive sleepiness associated with shift work disorder, treated obstructive sleep apnea, or narcolepsy using pharmacokinetic/pharmacodynamic models.

*Mona Darwish, PhD*<sup>1</sup>, Lauren S. Young, BSc<sup>1</sup>, Mary Kirby, MS<sup>1</sup>, Farkad Ezzet, MS, PhD<sup>2</sup>; (1)Clinical Pharmacology Department, Cephalon, Inc., Frazer, PA; (2)Strategic Consulting Services, Pharsight Corporation, Mountain View, CA

### **Urology**

210E. Assessment Of Cardiovascular (CV) Comorbidity In Patients With Overactive Bladder (OAB).

*Jaewhan Kim, PhD*<sup>1</sup>, Carl Asche, PhD<sup>1</sup>, Kristijan Kahler, RPh, PhD<sup>2</sup>, *Amit S. Kulkarni, PhD*<sup>2</sup>, Karl-Eric Andersson, MD, PhD<sup>3</sup>; (1)Pharmacotherapy Outcomes Research Center, Salt Lake City, UT; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)Wake Forest University, Winston-Salem, NC

211E. Pharmacokinetics and safety of silodosin in subjects with moderate liver dysfunction.

*Lawrence A. Hill, RPh, PharmD*, Weining Volinn, MS, Gary Hoel, RPh, PhD; Watson Laboratories, Salt Lake City, UT

## **CLINICAL PHARMACY FORUM**

### **ADR/Drug Interactions**

212. Evaluation of Medication Errors via a Computerized Physician Order Entry System in an Inpatient Renal Transplant Unit.

*Kwaku Marfo, PharmD*, Daniel Garcia, PharmD, Saira Khalique, PharmD, Amy Lu, MD, Karen Berger, BA; Montefiore Medical Center, Bronx, NY

### **Ambulatory Care**

214. Evaluation of hypertension management in patients treated in the pharmacist-run outpatient pharmacotherapy clinics at Grady Health System.

*Crystal M. Calloway, PharmD*<sup>1</sup>, Akilah Strawder, PharmD<sup>1</sup>, Nurcan Ilksoy, MD<sup>2</sup>; (1)Grady Health System, Atlanta, GA; (2)Emory University School of Medicine, Atlanta, GA

215. Diabetic nephropathy guideline adherence among family medicine physicians.

*Ashley Trull, Pharm.D.*<sup>1</sup>, *Renee M. DeHart, Pharm.D.*<sup>2</sup>; (1)Samford University McWhorter School of Pharmacy, Birmingham, AL; (2)University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR

216. Pharmacist medication reconciliation in a primary care setting.

*Autumn L. Runyon, PharmD.*<sup>1</sup>, Kevin J. Lynch, PharmD, BCPS<sup>2</sup>, Christine Tumis, PharmD<sup>3</sup>, Suzanne Higginbotham, PharmD<sup>1</sup>, Hildegard J. Berdine, Pharm.D., BCPS<sup>4</sup>; (1)Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA; (2)Pfizer, Inc, Upper St. Clair, PA; (3)Duquesne University, Pittsburgh, PA; (4)Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA

217. Development of a Clinical Pharmacy Services Provider Network for homeless patients.

*Leticia R. Moczygemba, PharmD, PhD*<sup>1</sup>, Gary R., Matzke, PharmD<sup>1</sup>, Sharon B. S. Gatewood, PharmD<sup>1</sup>, Akash Alexander, PharmD<sup>1</sup>, Amy Kennedy, PharmD<sup>1</sup>, Robert D. Osborn, MSW<sup>2</sup>, Jean-Venable R. Goode, PharmD<sup>1</sup>, Dianne Reynolds-Cane, MD<sup>2</sup>; (1)Virginia Commonwealth University School of Pharmacy, Richmond, VA; (2)Daily Planet, Inc., Richmond, VA

218. Implementation and Results of a Pharmacist-Led Hypertension Clinic.

Kimberly L. Liang, Pharm.D., Daniel F. Seidensticker, MD, Christopher B. Haas, DO; Naval Medical Center San Diego, San Diego, CA

219. Clinical pharmacist impact on lowering hemoglobin A1C in patients with diabetes.

Kevin J. Bacigalupo, Pharm.D., Frank J. Svete, Pharm.D., BCPS, Todd Lee, Ph.D., Pharm.D.; Edward Hines Jr. VA Hospital, Hines, IL

220. Evaluation of the therapeutic use and monitoring of outpatient amiodarone therapy in a Veterans Administration population.

Erika J. Briegel, Pharm., D., Arthur L. Allen, Pharm. D., CACP, Scott E. Mambourg, Pharm. D., BCPS, William F. Graetinger, M.D., FACC; Veterans Administration Sierra Nevada Health Care System, Reno, NV

221. Development of a Comprehensive Clinical Pharmacy Service (CCPS) practice model in a health care for the homeless clinic.

Jean-Venable R. Goode, PharmD<sup>1</sup>, Amy K. Kennedy, PharmD<sup>1</sup>, Leticia R. Moczygemba, PharmD, PhD<sup>1</sup>, Sharon B. S. Gatewood, PharmD<sup>1</sup>, Akash J. Alexander, PharmD<sup>1</sup>, Robert D. Osborn, MSW<sup>2</sup>, Gary R. Matzke, PharmD<sup>1</sup>, Dianne Reynolds-Cane, MD<sup>2</sup>; (1)Virginia Commonwealth University School of Pharmacy, Richmond, VA; (2)Daily Planet, Inc., Richmond, VA

222. Relationship between medication intolerance and achieving therapeutic goals for hypertension, diabetes, and hyperlipidemia.

Julianna M. Kula, Pharm.D.<sup>1</sup>, James D. Hoehns, Pharm.D.<sup>2</sup>, Michelle L. Graham, M.D.<sup>1</sup>, John E. Sutherland, M.D.<sup>1</sup>, Robert Greenwood, R.Ph.<sup>3</sup>, Erin E. Thatcher, B.A., Biochemistry<sup>4</sup>; (1)NEIFPC, Waterloo, IA; (2)University of Iowa College of Pharmacy/Northeast Iowa Family Practice Center, Waterloo, IA; (3)Greenwood Pharmacy, Waterloo, IA; (4)University of Iowa, Iowa City, IA

223. Pharmacist-physician collaboration to improve hyperlipidemia treatment among diabetic patients.

Doug Hansen, Pharm.D.<sup>1</sup>, Chris Accola, Pharm.D., PA-C<sup>1</sup>, James D. Hoehns, Pharm.D.<sup>2</sup>, John E. Sutherland, M.D.<sup>1</sup>; (1)Northeast Iowa Family Practice Center, Waterloo, IA; (2)University of Iowa College of Pharmacy/Northeast Iowa Family Practice Center, Waterloo, IA

224. Establishment of a pharmacist-managed pharmacotherapy clinic.

Heidi M. Wood, Pharm.D., Erica F. Pearce, Pharm.D., Kathleen E. Horner, Pharm.D., BCPS, Deanna L. McDanel, Pharm.D., BCPS, Ryan B. Jacobsen, Pharm.D., BCPS, Lisa A. Mascardo, Pharm.D.; University of Iowa Hospitals and Clinics, Iowa City, IA

### **Antimicrobial Stewardship**

225. Impact of pharmacists on the management of Clostridium difficile associated disease in a community hospital.

Janice R. McDonough, Pharm.D., Kenneth R. Eugenio, Pharm.D., Robert A. Motha, R.Ph., M.B.A.; St. Luke's Hospital, New Bedford, MA

### **Clinical Administration**

230. A Randomized Double-blind (withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrease-MT Capsules Compared with Placebo in the Treatment of Subjects with Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency.

Gerhard J. Leitz, MD, PhD, Andrew Mulberg, MD, Silber Steven, MD; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Titusville

231. Financial justification of a clinical pharmacist anticoagulation service at Intermountain Medical Center.

Nannette M. Berensen, PharmD, MBA, BCPS<sup>1</sup>, Missy Skelton Duke, PharmD<sup>2</sup>, Jeff A. Jensen, MBA<sup>1</sup>, Bruce E. Leavitt, PharmD, BCPS<sup>1</sup>, Jeffery L. Olson, PharmD, BCPS<sup>1</sup>, Russell K. Hulse, MBA<sup>1</sup>; (1)Intermountain Medical Center, Murray, UT; (2)Intermountain Healthcare, Salt Lake City, UT

### **Drug Information**

237. Impact of Seamless Care at a Traumatology Ward.

Charlotte Delobel, PharmD<sup>1</sup>, Sarah Mertens, PharmD<sup>1</sup>, Verdonk René, MD, PhD<sup>2</sup>, Hugo Robays, PharmD<sup>1</sup>; (1)Ghent University Hospital, Pharmacy Dpt, Ghent, Belgium; (2)Ghent University Hospital, Dept. of Orthopaedic Surgery and Traumatology, Ghent, Belgium

### **Drugs in pregnancy**

238. Assessment of Pregnancy Risk Categorization for Non-FDA Approved Medications Available in Saudi Arabian Market.

Sakra S. Balhareth, BSc., Pharm, Ahmed H. Aljedai, Pharm.D., M.B.A., BCPS, FCCP, Roa'a A. Algain, BSc.Pharm; King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

### **Family Medicine**

248. Evaluation of beliefs about hypertension in a general population.

Sarah E. McBane, PharmD; Duke University and Campbell University, Durham, NC

### **Health Services Research**

249. Correlation Between the Use of Gender and Ethnicity Specific Teaching Aids and Patient Acceptance Rate of the Pneumococcal Vaccine in an Inpatient Setting.

Vicken Yaghjian, PharmD<sup>1</sup>, Svetlana Simkhovich, PharmD<sup>1</sup>, Igal Khorshidi, MD<sup>1</sup>, Keith Veltri, Pharm.D.<sup>2</sup>; (1)Montefiore Medical Center, Bronx, NY; (2)Touro College of Pharmacy, New York, NY



## Hematology/Anticoagulation

250. A pilot study evaluating the impact and feasibility of a patient education and competency program for warfarin. *Lama H. Nazer, PharmD, BCPS, Purvy Shah, PharmD, Briana Ballard, PharmD, Seth Roffler, PharmD; Mount Sinai Hospital, Chicago, IL*

251. Impact of a pharmacist-based monitoring program on warfarin therapy in Home Based Primary Care veterans. *Jennifer T. Selvage, Pharm.D., Liancy Gomez, Pharm.D., BCPS, Kavita Palla, Pharm.D., BCPS, Eunha Lai, Pharm.D., CACP, Todd Lee, Ph.D., Pharm.D.; Edward Hines, Jr. VA Hospital, Hines, IL*

252E. Efficiency of an anticoagulation algorithm in patients undergoing intracardiac device implants. *Simon Tremblay, B.Pharm, M.Sc, Marie Robitaille, B.Pharm, M.Sc, Lyne Vaillancourt, RN, Sylvia Audet, B.Pharm, M.Sc, Geneviève Cyr, B.Pharm, M.Sc, Martine Lacroix, B.Pharm, M.Sc, Nicolas Noël, B.Pharm, M.Sc, Denis Brouillette, B.Pharm, D.P.H., Angela Nguyen, B.Pharm, M.Sc, Bernard Thibault, M.D.; Montreal Heart Institute, Montreal, QC, Canada*

253. Clinical outcomes of a pharmacist-managed anticoagulation discharge process for the prophylaxis and treatment of venous thromboembolism. *Melissa A. Reger, Pharm.D., Jamie L. Chapman, Pharm.D., Eric W. Mueller, Pharm.D., Dave M. Lutomski, M.S.; Department of Pharmacy Services, The University Hospital and Division of Pharmacy Practice, University of Cincinnati, Cincinnati, OH*

## Medication Safety

258. Pharmacist Intervention to Improve Prescribing Near Misses in Emergency Department. *Chia-Ching Lin, M<sup>1</sup>, Hui-Ping Liu, MSc<sup>1</sup>, You-Mei Lin, M<sup>2</sup>, Hsiu-Yu Chien, MS<sup>2</sup>; (1)Department of Pharmacy, Taipei Medical University-Shuang Ho Hospital, Jhonghe City, Taipei County, Taiwan; (2)1. Taipei Medical University, 2. Department of Pharmacy, Taipei Medical University-Shuang Ho Hospital, Jhonghe City, Taipei County, Taiwan*

259. Evaluation of an innovative corrected QT (QTc) monitoring and intervention program: A pilot study. *Ederlyn Dia, Pharm.D., Judy Davidson, C.N.S., Zubair Nadiri, B.A., Stein Joseph, M.D., Harminder Sikand, Pharm.D.; Scripps Mercy Hospital, San Diego, CA*

## Neurology

260. Pharmacist role in improving rate and quality of stroke specific education given to stroke patients/caregivers: A pre and post-intervention comparison.

*Paul Wohlt, PharmD, BCPS, Vinnie Watkins, RN, Elizabeth McKnight, MS, Dean Roller, MD, John Zurasky, MD; Intermountain Medical Center, Murray, UT*

## Pediatrics

263. Comparison of two different "Potassium-Cocktail" formulations used to lower serum potassium concentrations in neonates.

*Tracy Sandritter, Pharm.D., Alex Oschman, Pharm.D., Susanne Liewer, Pharm.D., Howard Kilbride, MD; Children's Mercy Hospital, Kansas City, MO*

264. Pharmacist managed therapeutic drug monitoring (TDM) in pediatric cystic fibrosis (CF) patients. *Jeffrey J. Cies, Pharm.D., BCPS<sup>1</sup>, Laurie Varlotta, MD<sup>2</sup>; (1)St. Christopher's Hospital for Children, Philadelphia, PA; (2)St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA*

265. Cost-savings with palivizumab in a pediatric hospital. *Jeffrey J. Cies, Pharm.D., BCPS; St. Christopher's Hospital for Children, Philadelphia, PA*

## Pharmacoeconomics/Outcomes

266. Continuous Quality Improvement of Darbepoetin Alfa (Aranesp)<sup>®</sup> Injections Administration Order Form (AAOF) to Assure Compliance with the 2007 Updated CMS Guidelines.

*Stacy L. Yang, Pharm., D.; Western University of Health Science, Monterey Park, CA*

267. Development and implementation of a STEP pharmacy.

*Janet D. Gaskins, MS<sup>1</sup>, Darrell L. Willyard, PharmD<sup>1</sup>, Gena Dupus, PharmD, BCPS<sup>2</sup>, Tony Palmer, RPh, MBA<sup>2</sup>, Steven Meixel, MD<sup>1</sup>; (1)University of Oklahoma School of Community Medicine, Tulsa, OK; (2)University of Oklahoma College of Pharmacy, Tulsa, OK*

## Pharmacogenomics/Pharmacogenetics

268. Evaluation of genetic and non-genetic factors on clinical response to Clopidogrel (Plavix) after Percutaneous Coronary Intervention in Iranian patients. *Soha Namazi, PharmD, PhD, Negar Azarpira, MD, Pathologist, Andia Khalili, PharmD, Mohammadjavad Kojuri, MD, Cardiologist; Shiraz University of Medical Sciences, Shiraz, Iran*

## RESIDENTS AND FELLOWS RESEARCH IN PROGRESS

### Ambulatory Care

273. Cost savings associated with pharmacist-assisted enrollment into prescription assistance programs. *Christine Tumis, PharmD<sup>1</sup>, Autumn L. Runyon, PharmD<sup>2</sup>, Thomas J. Mattei, Pharm.D.<sup>3</sup>; (1)Duquesne University, Pittsburgh, PA; (2)Duquesne University, Mylan School of*

Pharmacy, Pittsburgh, PA; (3)Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA

### **Cardiovascular**

274. An evaluation of clopidogrel use after non-ST-elevation and ST-elevation acute coronary syndrome. *Shelley E. Snell, Pharm.D.*<sup>1</sup>, Jessica Starr, PharmD, BCPS<sup>2</sup>; (1)Princeton Baptist Medical Center, Birmingham, AL; (2)Auburn University Harrison School of Pharmacy, Birmingham, AL

275. Inappropriate digoxin use and patient outcomes. *Kathryn S. Voll, Pharm.D.*<sup>1</sup>, Jessina C. McGregor, PhD<sup>2</sup>, Harleen Singh, Pharm.D.<sup>3</sup>; (1)Portland VA Medical Center, Portland, OR; (2)Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR; (3)Oregon State Univ., College of Pharmacy, Portland, OR

### **Hematology/Anticoagulation**

279. Impact of hospital guidelines on argatroban use in patients with suspected or confirmed heparin-induced thrombocytopenia: evaluation of clinical outcomes, adverse events and cost.

*Snehal H. Bhatt, PharmD, BCPS*, Wendy T. Chen, PharmD, Katherine Cunningham, PharmD; Beth Israel Deaconess Medical Center, Boston, MA

### **Infectious Diseases**

280. The Effect of Doxycycline on Sputum Biomarkers of Inflammation and Airway Remodeling in Patients with Cystic Fibrosis.

*Heather M. Owens, Pharm.D., M.S.*<sup>1</sup>, Ayana Boyd-King, M.D.<sup>2</sup>, Kamyar Afshar, M.D.<sup>2</sup>, Adupa Rao, M.D.<sup>2</sup>, Paul M. Beringer, Pharm.D.<sup>1</sup>; (1)University of Southern California, Los Angeles, CA; (2)University of Southern California, Los Angeles

### **Pharmacokinetics/Pharmacodynamics/Drug**

281. Pharmacodynamic evaluation of protein binding of antibiotics in critically ill patients.

*Ashley D. Hall, Pharm.D.*<sup>1</sup>, Tyree H. Kiser, Pharm.D.<sup>2</sup>, Douglas N. Fish, PharmD<sup>2</sup>; (1)University of Illinois Chicago College of Pharmacy, Chicago, IL; (2)University of Colorado School of Pharmacy, Aurora, CO

## **RESEARCH INSTITUTE**

### **Hematology/Anticoagulation**

338. Evaluation of Bivalirudin versus Heparin for Maintaining Hemofilter Patency in Continuous Renal Replacement Therapy.

*Tyree H. Kiser, Pharm.D.*<sup>1</sup>, Robert MacLaren, PharmD<sup>1</sup>, Douglas N. Fish, PharmD<sup>1</sup>, Kathryn L. Hassell, MD<sup>2</sup>,

Isaac Teitelbaum, MD<sup>2</sup>; (1)University of Colorado School of Pharmacy, Aurora, CO; (2)University of Colorado School of Medicine, Aurora, CO

### **Pediatrics**

339. Drug safety in pediatric patients.

*Rusudan G. Jashi, Dr., of, medicine, Professor*; Scientific Research Institute of Pediatrics, Tbilisi, Georgia